310 related articles for article (PubMed ID: 35909538)
1. Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights.
Mei Y; Dong B; Geng Z; Xu L
Front Endocrinol (Lausanne); 2022; 13():911968. PubMed ID: 35909538
[TBL] [Abstract][Full Text] [Related]
2. The dysregulation of immune cells induced by uric acid: mechanisms of inflammation associated with hyperuricemia and its complications.
Li D; Yuan S; Deng Y; Wang X; Wu S; Chen X; Li Y; Ouyang J; Lin D; Quan H; Fu X; Li C; Mao W
Front Immunol; 2023; 14():1282890. PubMed ID: 38053999
[TBL] [Abstract][Full Text] [Related]
3. Phloretin ameliorates hyperuricemia-induced chronic renal dysfunction through inhibiting NLRP3 inflammasome and uric acid reabsorption.
Cui D; Liu S; Tang M; Lu Y; Zhao M; Mao R; Wang C; Yuan Y; Li L; Chen Y; Cheng J; Lu Y; Liu J
Phytomedicine; 2020 Jan; 66():153111. PubMed ID: 31790902
[TBL] [Abstract][Full Text] [Related]
4. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
Kim SH; Lee SY; Kim JM; Son CN
Korean J Intern Med; 2020 Jul; 35(4):998-1003. PubMed ID: 30959584
[TBL] [Abstract][Full Text] [Related]
5. Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease.
Yanai H; Adachi H; Hakoshima M; Katsuyama H
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502127
[TBL] [Abstract][Full Text] [Related]
6. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.
Mallat SG; Al Kattar S; Tanios BY; Jurjus A
Curr Hypertens Rep; 2016 Oct; 18(10):74. PubMed ID: 27696189
[TBL] [Abstract][Full Text] [Related]
7. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
Hisatome I; Li P; Miake J; Taufiq F; Mahati E; Maharani N; Utami SB; Kuwabara M; Bahrudin U; Ninomiya H
Circ J; 2021 Jan; 85(2):130-138. PubMed ID: 33342914
[TBL] [Abstract][Full Text] [Related]
8. Uric acid and chronic kidney disease: which is chasing which?
Johnson RJ; Nakagawa T; Jalal D; Sánchez-Lozada LG; Kang DH; Ritz E
Nephrol Dial Transplant; 2013 Sep; 28(9):2221-8. PubMed ID: 23543594
[TBL] [Abstract][Full Text] [Related]
9. Advanced kidney failure and hyperuricemia.
Murea M
Adv Chronic Kidney Dis; 2012 Nov; 19(6):419-24. PubMed ID: 23089278
[TBL] [Abstract][Full Text] [Related]
10. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
Kuriyama S
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):1-5. PubMed ID: 31754883
[TBL] [Abstract][Full Text] [Related]
11. Anti-inflammatory and uric acid lowering effects of Euodiae fructus on hyperuricemia and gout mice.
Wang Z; Liu J; Mou Y; Liao W; Li Y; Liu J; Tang J
Front Pharmacol; 2024; 15():1296075. PubMed ID: 38708084
[TBL] [Abstract][Full Text] [Related]
12. Hereditary nephropathy associated with hyperuricemia and gout.
Puig JG; Miranda ME; Mateos FA; Picazo ML; Jiménez ML; Calvin TS; Gil AA
Arch Intern Med; 1993 Feb; 153(3):357-65. PubMed ID: 8427538
[TBL] [Abstract][Full Text] [Related]
13. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Hu AM; Brown JN
Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic insights into hyperuricemia-associated renal abnormalities with special emphasis on epithelial-to-mesenchymal transition: Pathologic implications and putative pharmacologic targets.
Balakumar P; Alqahtani A; Khan NA; Mahadevan N; Dhanaraj SA
Pharmacol Res; 2020 Nov; 161():105209. PubMed ID: 32979505
[TBL] [Abstract][Full Text] [Related]
15. The biology of urate.
Keenan RT
Semin Arthritis Rheum; 2020 Jun; 50(3S):S2-S10. PubMed ID: 32620198
[TBL] [Abstract][Full Text] [Related]
16. Research progress on related mechanisms of uric acid activating NLRP3 inflammasome in chronic kidney disease.
Wang M; Lin X; Yang X; Yang Y
Ren Fail; 2022 Dec; 44(1):615-624. PubMed ID: 35382689
[TBL] [Abstract][Full Text] [Related]
17. Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy.
Kim SM; Lee SH; Kim YG; Kim SY; Seo JW; Choi YW; Kim DJ; Jeong KH; Lee TW; Ihm CG; Won KY; Moon JY
Am J Physiol Renal Physiol; 2015 May; 308(9):F993-F1003. PubMed ID: 25651569
[TBL] [Abstract][Full Text] [Related]
18. Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney Disease.
Sellmayr M; Hernandez Petzsche MR; Ma Q; Krüger N; Liapis H; Brink A; Lenz B; Angelotti ML; Gnemmi V; Kuppe C; Kim H; Bindels EMJ; Tajti F; Saez-Rodriguez J; Lech M; Kramann R; Romagnani P; Anders HJ; Steiger S
J Am Soc Nephrol; 2020 Dec; 31(12):2773-2792. PubMed ID: 32938648
[TBL] [Abstract][Full Text] [Related]
19. Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation.
Meng ZQ; Tang ZH; Yan YX; Guo CR; Cao L; Ding G; Huang WZ; Wang ZZ; Wang KD; Xiao W; Yang ZL
Am J Chin Med; 2014; 42(6):1471-83. PubMed ID: 25384446
[TBL] [Abstract][Full Text] [Related]
20. Uric acid en route to gout.
Zhang WZ
Adv Clin Chem; 2023; 116():209-275. PubMed ID: 37852720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
